Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients

Autoři	WEINBERGEROVÁ Barbora MAYER Jiří KABUT Tomáš HRABOVSKÝ Štěpán PROCHÁZKOVÁ Jiřina KRÁL Zdeněk HEROUT Vladimír PACASOVÁ Rita ZDRAŽILOVÁ DUBSKÁ Lenka HUSA Petr BEDNAR Petr RUZEK Daniel LENGEROVÁ Martina
Rok publikování	2021
Druh	Článek v odborném periodiku
Časopis / Zdroj	Hematological Oncology
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://onlinelibrary.wiley.com/doi/10.1002/hon.2908
Doi	http://dx.doi.org/10.1002/hon.2908
Klíčová slova	COVID-19; remdesivir; hematological patients
Popis	Immunocompromised patients with hematological malignancies are at high risk for a severe course of COVID-19 (Coronavirus Disease 2019) with a deadly outcome.1, 2 With remdesivir use, several randomized trials have recorded abbreviated recovery periods, lower mortality, and positive consequences of early treatment initiation.3, 4 Based on randomized trial results, the FDA has approved remdesivir for the treatment of COVID-19. Regarding convalescent plasma (CP), evidence from recently published large trials implies that early administration of high-titer CP is most efficacious.5 However, no published studies assessing the effect of remdesivir or CP in COVID-19 have included a substantial proportion of hematooncology patients, and available data are limited to case reports.6, 7 In view of this dearth of data, we decided to analyze the efficacy of early combination therapy of remdesivir and high-titer CP among hematological patients. This treatment strategy was implemented after observing several grim COVID-19 outcomes among these patients.